Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” It appears above the page’s 403 error message.
    Difference
    1%
    Check dated 2026-10-24T16:17:50.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T16:10:04.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer identifies the site as revision v3.7.1 instead of v3.7.0. The study record continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:59:56.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    A 403 Forbidden error now displays on the study details page, replacing the content that previously showed trial information. This prevents users from viewing enrollment details, eligibility criteria, and contact information.
    Difference
    0.5%
    Check dated 2026-09-26T17:04:33.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page renders a 403 Forbidden error with the site chrome visible, replacing the expected study details and related navigation. This indicates an access issue rather than an update to study content.
    Difference
    17%
    Check dated 2026-09-19T18:34:59.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5, indicating a small update to page metadata/UI without changes to the trial details.
    Difference
    0.0%
    Check dated 2026-08-29T19:26:39.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.